Search results
Results From The WOW.Com Content Network
Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 6% on Friday, amid huge volumes. Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session Skip to main content
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody -based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle ), is the industry leader in antibody-drug conjugates or ADCs ...
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 4475.00% and 166.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...
For premium support please call: 800-290-4726 more ways to reach us
Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies. In May 2014, Alder went public. [1] In early 2018, the company made a public stock offering, aiming to raise US$250 million. [2]
For premium support please call: 800-290-4726 more ways to reach us
The Nasdaq-100 (^NDX) is a stock market index made up of equity securities issued by 100 of the largest non-financial companies listed on the Nasdaq stock exchange. It is a modified capitalization-weighted index.
Seattle Genetics, a cancer-focussed drug developer, will receive an upfront payment of $600 million under the agreement, while Merck will invest the $1 billion to buy 5 million shares of Seattle ...